Table 3.

Statistical analysis of the likelihood of FDA approval of targets in IBD [related to Fig. 5B–D].

Red denotes, S > 3.0 or P < 0.1 or presence on both continuum paths.

Blue denotes strong Boolean relationship (PRKAB1 high = > X high) of genes (or targets) that should not be targeted with antagonists.

^aApproved but withdrawn later due to side effects.

^b(TEST) Indicates either ongoing Phase III, pending FDA status, or untested targets.

^cUstekinumab.

^dRisankizumab.

^eApproved for CD, pending approval for UC.

^fEtanercept (soluble TNFR2 ectodomain), binds both TNFα and LTα.

^gIndeterminate mechanism of action [direct cytotoxic effect on mAb-coated target cell has been proposed].

^hMultiple anti-TNFα-specific mAbs that antagonize TNFR1/2; signaling.

ⁱMore effective in UC than CD.

^jTofacitinib (JAK1-3/TYK2 inhibitor) approved for UC, failed in CD; multiple other JAK1/3 orJAK1 inhibitors are in Phase III.

^kApilimod mesylate [STA5326]